Any current/future new fundraising through debt or equity?

The transcript provided does not mention any current or future plans for fundraising through debt or equity by Anthem Biosciences Limited. There is no discussion about issuing new shares, raising capital, or taking on additional debt in the Q3 & 9M FY26 earnings call. The focus is primarily on organic growth through investments in technology, capacity expansion (e.g., Unit-4 CAPEX), and operational performance. Management emphasizes strong financial health with growing EBITDA and PAT margins, but no specific fundraising plans are disclosed. Any future fundraising, if planned, was not c

Any current/future capex/capital investment/strategic investment?

Unit-4 Expansion: Rs. 1,000 crore CAPEX planned over two years for Unit-4 on a 30-acre land parcel; currently in early stage with ongoing civil work. Major CAPEX spend expected in FY27. New Capacity for Biosimilars: A separate new facility planned for CHO cell-based mammalian biosimilars beyond current 200-liter capacity. 16 KL Peptide Facility: Replacement cost estimated at about Rs. 200 crore including utilities; already commissioned a state-of-the-art 16 KL commercial peptide manufacturing facility. Capacity Planning: Expansion is done proactively based on pipeline progress to attract and h

Future growth expectations in sales/revenue/volumes?

Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year. Improvement anticipated in FY27 and FY28, with optimism about returning to approximately 20% growth CAGR over the next five years. Growth drivers include ramp-up of recently commercialized products, existing commercial products expanding market share, new large pharma customers, and increased demand post-destocking. Pipeline is robust with 130-140 early-stage molecules and 6 in Phase-2 likely to move to Phase-3 in 18-30 months. Positive outlook on biotech sector tailwinds

Future growth expectations in earnings/operating earnings/profits/EPS?

Anthem Biosciences expects steady topline and bottom-line growth with potential to sustain a CAGR similar to the last five years over the next few years. FY27 growth visibility is positive but uncertain; management is optimistic but cautious due to market lumpiness. Q4 FY26 typically strongest quarter; full-year revenue growth expected around mid-teens (15-16%). EBITDA margin trending north with aspirations to maintain or improve above 40%; full-year FY26 EBITDA growth guidance is 20%+. PAT margin expected to remain strong, with 20%+ growth guidance for FY26. Growth drivers include ramp-up of

Current/ Expected Orderbook/ Pending Orders?

Anthem Biosciences currently has a robust order book with around 130 to 140 early-stage pipeline molecules. Approximately 5 to 6 molecules are in Phase 2, expected to move to Phase 3 within 18 to 30 months, subject to clinical outcomes. Six molecules remain in Phase 3, with 4 recently commercialized. The company has added multiple large pharma customers this year, including supply of advanced intermediates and development work for approved products. There has been an increase in requests for RFQs (Request for Quotations) in recent quarters, indicating growing demand. Anthem is seeing signs of

IN US

Sale is live|00:00:00left today

Anthem Biosciences LtdQ4 FY27Pharmaceuticals & Biotechnology

Anthem Biosciences Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹769P/E: 87.5Market Cap: ₹44.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year.
→Improvement anticipated in FY27 and FY28, with optimism about returning to approximately 20% growth CAGR over the next five years.
→Growth drivers include ramp-up of recently commercialized products, existing commercial products expanding market share, new large pharma customers, and increased demand post-destocking.
→Pipeline is robust with 130-140 early-stage molecules and 6 in Phase-2 likely to move to Phase-3 in 18-30 months.
→Positive outlook on biotech sector tailwinds due to government encouragement and trade deals.
→GLP-1 peptides expected to become significant contributors, though not exceeding 20%-30% of turnover.
→Specialty ingredients growth driven by GLP-1, probiotics, and biosimilars.
→Margin improvements expected to sustain due to backward integration and operating leverage.

Margin guidance

Category 3

→Anthem Biosciences expects steady topline and bottom-line growth with potential to sustain a CAGR similar to the last five years over the next few years.
→FY27 growth visibility is positive but uncertain; management is optimistic but cautious due to market lumpiness.
→Q4 FY26 typically strongest quarter; full-year revenue growth expected around mid-teens (15-16%).
→EBITDA margin trending north with aspirations to maintain or improve above 40%; full-year FY26 EBITDA growth guidance is 20%+.
→PAT margin expected to remain strong, with 20%+ growth guidance for FY26.
→Growth drivers include ramp-up of recently commercialized products, expansion in specialty ingredients (GLP-1, probiotics, biosimilars), and increased capacity (Unit-4 CAPEX underway).
→Destocking pressures affecting recent quarters expected to normalize, leading to stronger demand in coming years.
→Currency appreciation benefits recognized as other income supporting margins.
→Overall outlook remains positive given regulatory, trade improvements, and expanded customer base.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript provided does not mention any current or future plans for fundraising through debt or equity by Anthem Biosciences Limited.
→There is no discussion about issuing new shares, raising capital, or taking on additional debt in the Q3 & 9M FY26 earnings call.
→The focus is primarily on organic growth through investments in technology, capacity expansion (e.g., Unit-4 CAPEX), and operational performance.
→Management emphasizes strong financial health with growing EBITDA and PAT margins, but no specific fundraising plans are disclosed.
→Any future fundraising, if planned, was not communicated in the available excerpts from the February 2026 earnings call.

Order book

→Anthem Biosciences currently has a robust order book with around 130 to 140 early-stage pipeline molecules.
→Approximately 5 to 6 molecules are in Phase 2, expected to move to Phase 3 within 18 to 30 months, subject to clinical outcomes.
→Six molecules remain in Phase 3, with 4 recently commercialized.
→The company has added multiple large pharma customers this year, including supply of advanced intermediates and development work for approved products.
→There has been an increase in requests for RFQs (Request for Quotations) in recent quarters, indicating growing demand.
→Anthem is seeing signs of recovery post-destocking by customers, which had temporarily softened performance.
→The management anticipates continued strong order inflow and a positive outlook, supported by new product launches and expansion in biotech and specialty ingredients segments.

Capex plans

Yes

→Unit-4 Expansion: Rs. 1,000 crore CAPEX planned over two years for Unit-4 on a 30-acre land parcel; currently in early stage with ongoing civil work. Major CAPEX spend expected in FY27.
→New Capacity for Biosimilars: A separate new facility planned for CHO cell-based mammalian biosimilars beyond current 200-liter capacity.
→16 KL Peptide Facility: Replacement cost estimated at about Rs. 200 crore including utilities; already commissioned a state-of-the-art 16 KL commercial peptide manufacturing facility.
→Capacity Planning: Expansion is done proactively based on pipeline progress to attract and handle more projects; focus on Greenfield builds to meet high regulatory and customer standards.
→Backward Integration: Completed discontinuation of China-sourced intermediates, now fully backward integrated, contributing to margin improvements and strategic self-reliance.

How does Anthem Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Anthem Biosciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Anthem Biosciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio